Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 8, 311 - 312 (2002)
doi:10.1038/nm0402-311b
Poor sales trigger vaccine withdrawal
Emma Hitt1
- Atlanta
Poor sales have prompted GlaxoSmithKline (GSK) to withdraw its Lyme disease vaccine, LYMErix, from the United States market. Lawsuits relating to adverse effects of the vaccine have been filed since its introduction, but the US Food and Drug Administration (FDA) found no proof that LYMErix is dangerous.
To read this story in full you will need to login or make a payment (see right).
